By earn Aurobindo Pharma | USFDA Approval
– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray.
– This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company
Please follow and like us:
